Lir Life SciencesBBCMF -80.00%15 PB Ratio is 1.79 as of Jun. 24, 2026. GuruFocus rates BBCMF with a GF Score™ of 15/100. Among 1,233 Biotechnology companies, Lir Life Sciences ranks worse than 85.81% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Lir Life Sciences PB Ratio Related Terms
Lir Life Sciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Lir Life Sciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lir Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lir Life Sciences PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lir Life Sciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Lir Life Sciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Lir Life Sciences (BBCMF) has a PB Ratio of 1.79 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lir Life Sciences and its competitors. According to the industry distribution chart, Lir Life Sciences ranks #1058 out of 1233 companies in the Biotechnology industry, placing it in the top 85.8%.
Is Lir Life Sciences' PB Ratio too high?
Lir Life Sciences' current PB Ratio is 1.79. The Biotechnology industry median PB Ratio is 2.83. Lir Life Sciences' value of 1.79 is 36.7% below this industry median. Based on the distribution chart, Lir Life Sciences ranks #1058 out of 1233 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lir Life Sciences has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Lir Life Sciences' PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lir Life Sciences ranks #1058 out of 1233 companies for PB Ratio. This places Lir Life Sciences in the lower half of its industry. The industry median PB Ratio is 2.83. Lir Life Sciences' value of 1.79 is 36.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lir Life Sciences's current PB Ratio of 1.79 is 36.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Lir Life Sciences and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lir Life Sciences's current PB Ratio is 1.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lir Life Sciences stock overvalued right now?
Lir Life Sciences (BBCMF) has a current PB Ratio of 1.79. The current PB Ratio is 1.79 and 36.7% below the Biotechnology industry median of 2.83. Lir Life Sciences' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Lir Life Sciences (BBCMF), the current PB Ratio is 1.79 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address505-1505 West 2nd Avenue, Vancouver, BC, CAN, V6J 1H2
Lir Life Sciences Corp is a biotechnology company developing transdermal and sublingual drug-delivery technologies for GLP-1-based obesity therapies, with the focus of improving accessibility and patient experience.
15GF Score
Get the complete analysis for BBCMF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BBCMF has been successfully added to your 